adamas
presents
new
data
analysis
parkinson
disease
patients
dyskinesia
movement
disorder
society
virtual
congress
emeryville
globe
newswire
adamas
pharmaceuticals
nasdaq
adms
company
dedicated
developing
delivering
medicines
make
meaningful
difference
people
affected
neurological
diseases
announced
today
two
presentations
amantadine
extended
release
capsules
treatment
dyskinesia
patients
parkinson
disease
receiving
therapy
movement
disorder
society
mds
virtual
congress
september
presentations
provide
evidence
gocovri
may
reduce
time
people
parkinson
prolonged
effects
least
two
years
said
jean
hubble
md
vice
president
medical
affairs
adamas
dyskinesia
disrupt
daily
activities
people
pd
treating
dyskinesia
come
expense
increased
vice
versa
patients
seek
good
time
reductions
dyskinesia
providers
consider
gocovri
treatment
option
shown
provide
substantial
sustained
following
posters
available
mds
virtual
poster
hall
beginning
september
poster
among
parkinson
disease
patients
dyskinesia
amantadine
reduces
disruptive
motor
episodes
improves
function
analysis
phase
trials
lead
author
robert
hauser
md
mba
usf
parkinson
disease
movement
disorders
center
parkinson
foundation
center
excellence
poster
effects
amantadine
extended
release
capsules
symptoms
parkinson
disease
patients
dyskinesia
analysis
ease
lid
trial
lead
author
caroline
tanner
md
phd
university
california
san
francisco
parkinson
disease
dyskinesia
parkinson
disease
pd
progressive
neurodegenerative
disorder
caused
gradual
loss
brain
cells
produce
neurotransmitter
dopamine
affects
approximately
one
million
people
united
states
dopamine
decline
brain
results
wide
range
motor
symptoms
disease
progresses
people
likely
experience
unpredictable
stiffness
rigidity
tremors
referred
time
primary
treatment
pd
levodopa
however
time
levodopa
may
lead
involuntary
uncontrolled
movements
known
dyskinesia
abrupt
unpredictable
transitions
episodes
dyskinesia
normal
movement
time
lead
considerable
impact
patients
lives
amantadine
capsules
first
medicine
indicated
treatment
dyskinesia
patients
parkinson
disease
receiving
therapy
without
concomitant
dopaminergic
medications
also
medicine
clinically
proven
reduce
dyskinesia
taken
daily
bedtime
gocovri
provides
initial
lag
slow
rise
amantadine
concentration
night
resulting
high
concentration
morning
throughout
waking
day
additionally
clinical
trials
adjunctive
use
gocovri
require
dose
changes
dopaminergic
therapies
commonly
observed
adverse
reactions
gocovri
hallucinations
dizziness
dry
mouth
peripheral
edema
constipation
falls
orthostatic
hypotension
information
gocovri
please
visit
important
safety
information
contraindications
contraindicated
patients
creatinine
clearance
ml
min
warnings
precautions
falling
asleep
activities
daily
living
somnolence
patients
treated
parkinson
disease
medications
reported
falling
asleep
activities
daily
living
patient
develops
daytime
sleepiness
activities
require
full
attention
driving
motor
vehicle
conversations
eating
gocovri
ordinarily
discontinued
patient
advised
avoid
potentially
dangerous
activities
suicidality
depression
monitor
patients
depression
including
suicidal
ideation
behavior
prescribers
consider
whether
benefits
outweigh
risks
treatment
gocovri
patients
history
suicidality
depression
hallucinations
psychotic
behavior
patients
major
psychotic
disorder
ordinarily
treated
gocovri
risk
exacerbating
psychosis
observe
patients
occurrence
hallucinations
throughout
treatment
especially
initiation
dose
increases
dizziness
orthostatic
hypotension
monitor
patients
dizziness
orthostatic
hypotension
especially
starting
gocovri
increasing
dose
hyperpyrexia
confusion
rapid
dose
reduction
abrupt
discontinuation
gocovri
may
cause
increase
symptoms
parkinson
disease
cause
delirium
agitation
delusions
hallucinations
paranoid
reaction
stupor
anxiety
depression
slurred
speech
avoid
sudden
discontinuation
gocovri
impulse
control
compulsive
behaviors
patients
may
experience
urges
gambling
sexual
money
spending
binge
eating
inability
control
important
prescribers
ask
patients
caregivers
development
new
increased
urges
consider
dose
reduction
stopping
medications
adverse
reactions
common
adverse
reactions
hallucination
dizziness
dry
mouth
peripheral
edema
constipation
fall
orthostatic
hypotension
please
see
full
prescribing
information
additional
important
safety
information
https
assets
pdfs
adamas
adamas
vision
clear
deliver
innovative
medicines
reduce
burden
neurological
diseases
patients
caregivers
society
fully
integrated
company
focused
growing
portfolio
therapies
address
range
neurological
diseases
information
please
visit
statements
statements
contained
press
release
regarding
matters
may
occur
future
statements
within
meaning
private
securities
litigation
reform
act
including
limited
statements
contained
press
release
regarding
adamas
expectations
full
year
expenses
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
description
risks
uncertainties
could
cause
actual
results
differ
expressed
statements
including
risks
relating
adamas
research
clinical
development
commercial
activities
relating
gocovri
regulatory
competitive
environment
adamas
business
general
see
adamas
quarterly
report
form
filed
securities
exchange
commission
august
particularly
caption
risk
addition
impact
current
pandemic
demand
gocovri
unknown
duration
severity
pandemic
add
additional
risk
uncertainty
statements
investors
cautioned
place
undue
reliance
statements
speak
date
release
adamas
undertakes
obligation
update
statement
press
release
except
required
law
contact
